

Press release – October 6<sup>th</sup>, 2016

## **26 European healthcare SMEs participate in a trade mission to Japan with bioXclusters Plus**

The European Strategic Cluster Partnership on Personalized Healthcare, bioXclusters *Plus* - gathering Biocat (Catalonia), BioM (Bavaria), BioPmed (Piedmont) and Lyonbiopole (Auvergne Rhone-Alpes) – organizes in collaboration with the EU Japan Centre **a mission to Japan from Oct 10<sup>th</sup> to 14<sup>th</sup> 2016**. The mission will take place in Osaka and Yokohama.

**The delegation is composed by the 4 clusters' representatives along with 26 SMEs\* from the bioXclusters *Plus*' regions.**

### **An agenda dedicated to SMEs and networking**

The company delegation will benefit, on October 10<sup>th</sup>, from one training day dedicated to acquiring knowledge about the Japanese healthcare sector, organized in cooperation with the EU-Japan Centre. On October 11<sup>th</sup>, the delegation will participate in a **dedicated “European Biotech & Pharma Partnering Conference” organized by bioXclusters *Plus* at the Senri-Life Science Center in Osaka, with the support of Osaka Bio Headquarters and the EU Japan Centre.**

On this occasion, more than **150 participants from Japanese and European life sciences and healthcare companies** will have the opportunity to network and meet in face-to-face meetings. Around 330 meetings are planned. This unique event has been built up thanks to a growing collaboration between the bioXclusters *Plus*' partners and its Osaka counterparts.

In the last three days, the full delegation will join the Bio Japan Conference in Yokohama, where European companies will have new opportunities to meet with other Japanese players. The Bio Japan convention is one of the largest event on biotechnologies in Asia, offering multiple business opportunities for companies with around 800 companies participating each year. Moreover, bioXclusters *Plus* will introduce the initiative to Japan during the Bio Cluster summit at Bio Japan, organized by the Japan Bioindustry Association (JBA) on October 13<sup>th</sup>.

*\*List of the 26 Companies participating: 2bind GmbH, 4SC AG, Ability Pharmaceuticals S.L., Apceth GmbH & Co. KG, Ascenion GmbH, Bioindustry Park Silvano Fumero SpA, Boeters & LieckCoriolis Pharma Research GmbH, CTIBiotech, CYTOO SA, FGK Clinical Research GmbH, Gams Wellness, genOway, Indicia Production, Iris Biotech GmbH, Klifovet AG, Laboratorios Rubió S.A, Laboratorios Salvat S.A., Leukocare AG, Leukos Biotech, Medigene AG, Mind the Byte S.L., Novotec, Theranexus, Thrombotargets Europe S.L., Zeclinics S.L.*



Partners:



## Developing long term strategic partnerships with Japan

Japan is one of the markets targeted by the bioXclusters *Plus*' alliance. Japan has the 2<sup>nd</sup> largest global market in healthcare after the US. It is characterized by high health expenditures per capita, the use of advanced technology and a high level of R&D facilities supported by successive development plans of the government.

With an increasingly ageing population, biotechnologies and medical technologies solutions are playing a strategic role in the evolution of the societal and economic challenges advocated by the public authorities from Japan and the European Union in the next years. Moreover, over the past few years, the pharma and medtech industry in Japan have been more and more willing to foster collaborations with external players and in particular with Europe. These factors strongly reinforce the attractiveness of the market for European players in particular SMEs.

For this reason, the bioXclusters *Plus*' priority is to offer SMEs the right tools to approach such strategic markets by showcasing European competences through a unique delegation united under a single banner maximizing their visibility.

In the next months, the alliance intends to build up a "direct Gateway" based in Japan for its European SMEs to reinforce their market access and foster business relationships with a fast-track dimension.

### About bioXclusters PLUS

*bioXclusters Plus is the leading European Strategic Cluster Partnership on Personalized Healthcare. It gathers four of the most dynamic and fastest growing life science and healthcare clusters in Europe (Catalonia, Bavaria, Piemonte, and Auvergne-Rhône-Alpes) and offers the best gateway to finding your partner in Europe.*

*bioXclusters plus represents 3,300 innovative, European SMEs focused on personalised healthcare (mainly in personalised medicine, oncology, cardiovascular, inflammatory, infectious diseases and the central nervous system), with a wide technological offer.*

*bioXclusters plus was selected by the European Union in 2016 in the framework of the COSME Programme. Its objectives are to offer an entry point for global players to Europe and build up gateways on strategic markets to foster international collaborations for European SMEs' benefit. Learn more on: <https://bioclusters.eu/about/>*

